Literature DB >> 9816541

The inhibitory effect of an EGF receptor-specific tyrosine kinase inhibitor on pancreatic cancer cell lines was more potent than inhibitory antibodies against the receptors for EGF and IGF I.

M Kobari1, B Kullenberg, A Björkman, S Matsuno, I Ihse, J Axelson.   

Abstract

CONCLUSION: Epidermal growth factor (EGF) increased the cell number of the two pancreatic cancer cell lines, MiaPaCa-2 and LN-36, in vitro. A blockade of the EGF-R tyrosine kinase with tyrphostin was more efficient in reducing the cell number than inhibiting receptor antibodies. IGF-1 increased the cell number, and blockade of the IGF-1-R initially decreased the cell number that later was followed by an increase in LN-36. BACKGROUND/AIM: The receptors and ligands of EGF and insulin-like growth factor-1 (IGF-1) are overexpressed in pancreatic cancer tissue. The aim of the present experiments was to study the effects of EGF and IGF-1 on the cell number in two pancreatic cancer cell lines.
MATERIAL AND METHODS: MiaPaCa-2 cells were grown in 0.2% fetal calf serum (FCS) and the newly established LN-36 cells in serum-free medium (SFM). The cell number was measured with the XTT method. The effects of EGF and IGF-1 were studied in combination with inhibiting receptor antibodies and an EGF-R-specific tyrosine kinase inhibitor, tyrphostin B56.
RESULTS: MiaPaCa-2 responded with increased cell number to stimulation with EGF, and at 10(-8) M or higher concentrations a dose-response pattern was seen. Administration of B56 to MiaPaCa-2 decreased the cell number by 87%. The inhibiting EGF-R-Ab only inhibited EGF-induced increase in cell number. IGF-1 doubled the cell number of MiaPaCa-2 and increased the cell growth induced by EGF. The inhibiting IGF-1-R-Ab reduced the cell number by 10%. The LN-36 cell line responded to EGF with an increased cell number with a maximum at 5 x 10(-9) M after 96 h. B56 reduced the cell number by 90% at 10(-5) M, with less effect during stimulation with EGF. In contrast to B56, the inhibiting EGF-R-Ab in the same experiment did not reduce the cell number. LN-36 responded to IGF-1 with an increased cell number, but EGF-stimulated growth was not influenced. The inhibiting IGF-1-R-Ab reduced the cell number and suppressed the IGF-1 stimulated increase after 24 h and later it induced an increased cell number.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9816541     DOI: 10.1007/BF02788565

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  36 in total

Review 1.  Growth factors in development, transformation, and tumorigenesis.

Authors:  M Cross; T M Dexter
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

2.  Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle.

Authors:  J J Smith; R Derynck; M Korc
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Binding and processing of epidermal growth factor in Panc-I human pancreatic carcinoma cells.

Authors:  M Korc; B E Magun
Journal:  Life Sci       Date:  1985-05-13       Impact factor: 5.037

4.  Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.

Authors:  A Gazit; P Yaish; C Gilon; A Levitzki
Journal:  J Med Chem       Date:  1989-10       Impact factor: 7.446

Review 5.  Apoptosis. Its significance in cancer and cancer therapy.

Authors:  J F Kerr; C M Winterford; B V Harmon
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

6.  Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop.

Authors:  H Lahm; P Amstad; J Wyniger; A Yilmaz; J R Fischer; M Schreyer; J C Givel
Journal:  Int J Cancer       Date:  1994-08-01       Impact factor: 7.396

7.  Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness.

Authors:  Y Yamanaka; H Friess; M S Kobrin; M Buchler; H G Beger; M Korc
Journal:  Anticancer Res       Date:  1993 May-Jun       Impact factor: 2.480

8.  Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies.

Authors:  C Mao; D R Domenico; K Kim; D J Hanson; J M Howard
Journal:  Arch Surg       Date:  1995-02

9.  Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells.

Authors:  T Kawamoto; J Mendelsohn; A Le; G H Sato; C S Lazar; G N Gill
Journal:  J Biol Chem       Date:  1984-06-25       Impact factor: 5.157

10.  Cytogenetic characterization of a periampullary adenocarcinoma of the pancreas, its liver metastasis, and a cell line established from the metastasis and a cell line established from the metastasis in a patient with Gardner's syndrome.

Authors:  G Bardi; P Aman; B Johansson; N Pandis; N Mandahl; E Bak-Jensen; A Björkman; H O Sjögren; A Andrén-Sandberg; F Mitelman
Journal:  Cancer Genet Cytogenet       Date:  1994-08
View more
  2 in total

1.  Transforming growth factor alpha (TGF-alpha) increases cell number in a human pancreatic cancer cell line but not in normal mouse pancreas.

Authors:  B Kullenberg; C Jansen; N Fredäng; B Ohlsson; J Axelson
Journal:  Int J Pancreatol       Date:  2000-12

Review 2.  Tyrosine kinase inhibitors in preclinical development.

Authors:  M L Levitt; P P Koty
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.